Publication / Source: Bioanalysis 8(3)
Authors: Bowen CL, Kehler J, Boram S
Background: FTIH studies can be challenging due to the varying dosing regimens and rapid data delivery. Chemists are asked to provide ultra-low limits of quantitation to provide an understanding of patient efficacy and safety in order to progress drug development. In a recent dermal study it became necessary to reduce the LLOQ of a small molecule drug from 50 to 1 pg/ml due to reductions in the dose and surface area of drug application. Methodology: The 50-fold increase in assay sensitivity necessitated the use of a high-resolution mass spectrometer (LC–HRMS) to separate matrix interferences observed when using a unit resolution triple quadrupole MS. Conclusion: A sensitive, robust assay was validated to support of a FTIH study using a LC–HRMS.